Home » Stocks » MEI Pharma

MEI Pharma, Inc. (MEIP)

Stock Price: $2.72 USD -0.06 (-2.16%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
After-hours: $2.79 +0.07 (2.57%) Aug 10, 7:55 PM

Stock Price Chart

Key Info

Market Cap 288.32M
Revenue (ttm) 4.54M
Net Income (ttm) -24.49M
Shares Out 106.00M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $2.72
Previous Close $2.78
Change ($) -0.06
Change (%) -2.16%
Day's Open 2.81
Day's Range 2.68 - 2.81
Day's Volume 575,499
52-Week Range 0.72 - 4.46

More Stats

Market Cap 288.32M
Enterprise Value 195.52M
Earnings Date (est) Sep 2, 2020
Ex-Dividend Date n/a
Shares Outstanding 106.00M
Float 78.23M
EPS (basic) -37035.8
EPS (diluted) -0.47
FCF / Share -0.41
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.41M
Short Ratio 2.36
Short % of Float 5.64%
Beta 1.76
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 63.52
PB Ratio 3.87
Revenue 4.54M
Operating Income -48.92M
Net Income -24.49M
Free Cash Flow -43.71M
Net Cash 92.80M
Net Cash / Share 0.88
Gross Margin 14.36%
Operating Margin -1,077.84%
Profit Margin -539.50%
FCF Margin -963.05%
ROA -33.50%
ROE -43.58%
ROIC 358.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$9.44*
(247.06% upside)
Low
5.50
Current: $2.72
High
13.00
Target: 9.44
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue4.921.6223.25-------
Revenue Growth203.02%-93.02%--------
Gross Profit0.65-1.7618.25-------
Operating Income-46.25-28.592.38-21.00-32.77-27.23-11.22-8.39-6.45-7.98
Net Income-16.82-40.072.67-20.86-32.69-27.15-11.19-7.52-6.78-7.90
Shares Outstanding71.1441.4336.8134.4028.2020.0610.162.251.271.22
Earnings Per Share-54,613.00-40,068.002,670.00-0.61-1.16-1.35-1.10-3.35-5.34-6.42
Operating Cash Flow-29.42-21.043.49-17.86-28.07-19.45-10.04-7.08-6.50-10.03
Capital Expenditures-0.22--0.05--0.02-0.05-0.04--0.05-
Free Cash Flow-29.64-21.043.44-17.86-28.08-19.50-10.08-7.08-6.55-10.04
Cash & Equivalents74.4910353.5745.9263.7848.7935.576.203.869.03
Net Cash / Debt74.4910353.5745.9263.7848.7935.576.203.869.03
Assets82.6610555.7047.1664.7549.8136.556.374.179.14
Liabilities34.7354.204.875.514.964.621.681.772.371.76
Book Value47.9350.4650.8441.6559.7945.1934.874.601.797.38
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name MEI Pharma, Inc.
Country United States
Employees 40
CEO Daniel P. Gold

Stock Information

Ticker Symbol MEIP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MEIP
IPO Date December 19, 2003

Description

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory follicular lymphoma and B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor for B-cell malignancies and AML. In addition, the company engages in the development of ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex for the treatment of HER2-negative breast cancer. MEI Pharma, Inc. has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacture, and commercialization of Pracinostat; and a license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor, as well as related compounds. The company also has a license agreement with CyDex Pharmaceuticals, Inc. for Captisol to use with ME-344, which are isoflavone-based drug compounds; a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of ME-401 in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies; and a license agreement with Kyowa Kirin Co., Ltd. for ME-401. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.